Developer docs
API playgroundTry for free, no card

Search company profiles

Pattern Bioscience

Full company profile

uuid0000gpc

Namestring
Pattern Bioscience
Legal namestring
Pattern Bioscience, Inc.
Websiteurl
pattern.bio
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Pattern Bioscience is an Austin, Texas-based clinical diagnostics company, founded in 2016 (originally as Klaris Diagnostics) and operating as a privately held Texas corporation. The company has developed a single-cell microbiology platform (branded Digital Culture™) that captures individual live bacterial cells in picovolume-scale droplets and analyzes their metabolic patterns via machine learning to deliver pathogen identification (ID) and antimicrobial susceptibility testing (AST) in hours rather than the 2–4 days required by conventional culture-based methods. Its primary customers are hospital clinical microbiology laboratories serving critically ill patients with suspected bacterial infections, particularly pneumonia, bacteremia, and urinary tract infections, where delays in targeted antibiotic therapy materially increase mortality and accelerate antimicrobial resistance. Pattern's core products are the lead Pneumonia ID/AST Panel, an in-development Bacteremia ID/AST Panel, and the underlying instrument and consumables platform; the platform's phenotypic approach is designed to capture all known and unknown resistance mechanisms rather than relying solely on genotypic markers.

The company is pre-commercial as of early 2026 with no product revenue and planned first U.S. commercial launch following FDA 510(k) clearance; revenue mechanics will rely on direct enterprise sales of the instrument platform and disposable assay panels to U.S. hospital laboratories, supported by a dedicated VP of Sales and product marketing leadership. Pricing is not publicly disclosed. Capitalization exceeds $148M in total funding, including a $28.7M Series C (April 2023), a $43M Series D (November 2025) co-led by AMR Action Fund, Illumina Ventures, and Omnimed Capital, a Form D exempt offering of approximately $61.22M (with $44.22M sold as of August 2025), a $6.8M CARB-X award plus a Series B (February 2020), a $9M Series B-1 (July 2020), and a $3.75M Series A (May 2018); non-dilutive capital is supplemented by a BARDA cost-share contract worth up to $40.9M awarded in November 2024.

Short descriptiontext

Pattern Bioscience is an Austin-based clinical diagnostics company developing a culture-free single-cell microbiology platform that delivers rapid pathogen identification and antimicrobial susceptibility testing for hospital microbiology labs treating critically ill patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid antimicrobial susceptibility testing, clinical microbiology diagnostics, single-cell microbiology platform, bacterial pathogen identification, antimicrobial resistance diagnostics
Industry2 codes
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Clinical Microbiology Diagnostics
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Platform and Assays
TypeHardware Sales
Description

Pattern Bioscience generates revenue through the sale of its single-cell microbiology diagnostic system and associated ID/AST assay panels (Pneumonia ID/AST Panel, Bacteremia ID/AST Panel). The company is pre-commercial as of early 2026, preparing for first U.S. commercial launch following FDA 510(k) clearance of the Pneumonia ID/AST Panel.

pattern.bio
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pattern Bioscience develops and plans to commercialize a single-cell microbiology (Digital Culture™) diagnostic platform that isolates individual live bacterial cells in picovolume-scale droplets and uses machine learning to interpret their metabolic patterns. The platform is intended to deliver pathogen identification and phenotypic antimicrobial susceptibility testing (ID/AST) directly from clinical specimens in hours instead of the 2–4 days required by traditional culture-based methods. Initial commercial products target the Pneumonia ID/AST Panel for critically ill pneumonia patients and the Bacteremia ID/AST Panel for bloodstream infections, sold to hospital clinical microbiology laboratories.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 50% of antibiotics prescribed in hospitals are unnecessary or inappropriate (CDC)
+4 more records
Product overview1 text field

Pattern Bioscience offers a single-cell microbiology platform as its core technology, with two primary test panels: the Pneumonia ID/AST Panel for respiratory infections and the Bacteremia ID/AST Panel for bloodstream infections. The platform bypasses traditional culture steps by isolating and analyzing individual bacterial cells captured in droplets, delivering rapid pathogen identification and phenotypic antimicrobial susceptibility results in hours rather than days. The Pneumonia Panel analyzes bacterial cells directly from respiratory specimens, while the Bacteremia Panel works directly from positive blood culture samples.

Product and service3 records
1Pattern Pneumonia ID/AST Panel
CategoryClinical microbiology diagnostic assay panel
Description

Rapid identification and phenotypic antimicrobial susceptibility testing (ID/AST) panel designed for critically ill patients hospitalized with severe pneumonia, delivering pathogen ID and susceptibility results in hours rather than the 2–4 days required by culture-based methods. Analyzes bacterial cells directly from respiratory specimens using single-cell microbiology, and received FDA Breakthrough Device Designation in December 2021.

2Pattern Bacteremia ID/AST Panel
CategoryClinical microbiology diagnostic assay panel
Description

Identification and phenotypic antibiotic susceptibility testing panel designed to identify pathogens and provide AST directly from positive blood culture samples, eliminating the need for additional culturing and isolation steps to obtain faster phenotypic susceptibility results for bloodstream infections.

3Single-Cell Microbiology (Digital Culture™) Diagnostic Platform
CategoryClinical microbiology diagnostic instrument platform
Description

Culture-free, rapid phenotypic testing platform that delivers clinically actionable bacterial identification and antimicrobial susceptibility results in hours. Uses single-cell isolation in picovolume-scale droplets combined with proprietary data science and machine learning to generate millions of measurements per run capturing all resistance mechanisms (known, unknown, genetic, epigenetic, simple, or complex) for the company's ID/AST panels.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor developing rapid phenotypic ID/AST for bloodstream and other serious infections; acquired by bioMérieux in 2022. Competes head-to-head with Pattern on the same hospital bench for time-to-AST in critical care settings.

TypeDirect peer
Description

Developed a rapid AST instrument using metabolomic signaling — the closest analogue to Pattern's single-cell approach. Acquired by bioMérieux in 2022; Pattern's VP Sales led sales at Specific prior to the acquisition.

3Qvella Corporation
TypeDirect peer
Description

Early-stage company developing rapid culture-free ID/AST directly from positive blood cultures, addressing the same unmet need as Pattern's Bacteremia ID/AST Panel and Bacteremia product roadmap.

TypeDirect peer
Description

Develops rapid phenotypic AST to deliver antibiotic susceptibility results in hours directly from clinical samples; competed against Pattern in the AMR Diagnostics Challenge and operates in the same FDA Breakthrough Designation / sepsis-decision-making category.

TypeDirect peer
Description

Develops T2Bacteria and T2Candida panels for direct-from-blood rapid identification without culture; overlaps with Pattern's bloodstream infection roadmap and the clinical unmet need around sepsis diagnostics.

TypeBroad incumbent
Description

Global leader in clinical microbiology (VITEK, BIOFIRE FilmArray, BACT/ALERT). Acquired both Accelerate Diagnostics and Specific Diagnostics. Sets the reimbursement and workflow precedent Pattern's commercial team must navigate.

TypeBroad incumbent
Description

Broad diagnostics incumbent offering the BD MAX molecular platform, BD Phoenix automated AST, and established MALDI workflow partnerships. Competes across ID/AST categories where Pattern plans to expand.

TypeBroad incumbent
Description

Operates the MALDI Biotyper, the dominant rapid MALDI-TOF identification workflow in clinical microbiology labs; the incumbent alternative to single-cell phenotypic ID that Pattern's Pneumonia Panel must displace or complement.

TypeBroad incumbent
Description

GeneXpert and Xpress systems are rapidly deployed across U.S. hospital microbiology labs for molecular diagnostics, including for bloodstream and respiratory panels, and represent the typical workflow that Pattern's phenotypic approach must clinically displace.

TypeBroad incumbent
Description

Acquired GenMark Diagnostics (eXpert rapid molecular) for ~$1.8B and operates cobas/coba platforms spanning microbiology and infectious disease; relevant as the strategic acquirer archetype for novel hospital diagnostics with KOL-led commercial traction.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pattern Bioscience

Clinical Microbiology Diagnosticspattern.bio

Pattern Bioscience is an Austin-based clinical diagnostics company developing a culture-free single-cell microbiology platform that delivers rapid pathogen identification and antimicrobial susceptibility testing for hospital microbiology labs treating critically ill patients.

What Pattern Bioscience does

Pattern Bioscience is an Austin, Texas-based clinical diagnostics company, founded in 2016 (originally as Klaris Diagnostics) and operating as a privately held Texas corporation. The company has developed a single-cell microbiology platform (branded Digital Culture™) that captures individual live bacterial cells in picovolume-scale droplets and analyzes their metabolic patterns via machine learning to deliver pathogen identification (ID) and antimicrobial susceptibility testing (AST) in hours rather than the 2–4 days required by conventional culture-based methods. Its primary customers are hospital clinical microbiology laboratories serving critically ill patients with suspected bacterial infections, particularly pneumonia, bacteremia, and urinary tract infections, where delays in targeted antibiotic therapy materially increase mortality and accelerate antimicrobial resistance. Pattern's core products are the lead Pneumonia ID/AST Panel, an in-development Bacteremia ID/AST Panel, and the underlying instrument and consumables platform; the platform's phenotypic approach is designed to capture all known and unknown resistance mechanisms rather than relying solely on genotypic markers.

The company is pre-commercial as of early 2026 with no product revenue and planned first U.S. commercial launch following FDA 510(k) clearance; revenue mechanics will rely on direct enterprise sales of the instrument platform and disposable assay panels to U.S. hospital laboratories, supported by a dedicated VP of Sales and product marketing leadership. Pricing is not publicly disclosed. Capitalization exceeds $148M in total funding, including a $28.7M Series C (April 2023), a $43M Series D (November 2025) co-led by AMR Action Fund, Illumina Ventures, and Omnimed Capital, a Form D exempt offering of approximately $61.22M (with $44.22M sold as of August 2025), a $6.8M CARB-X award plus a Series B (February 2020), a $9M Series B-1 (July 2020), and a $3.75M Series A (May 2018); non-dilutive capital is supplemented by a BARDA cost-share contract worth up to $40.9M awarded in November 2024.

Pattern Bioscience firmographics

Firmographics
Name
Pattern Bioscience
Legal name
Pattern Bioscience, Inc.
Website
https://pattern.bio
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Pattern Bioscience is an Austin-based clinical diagnostics company developing a culture-free single-cell microbiology platform that delivers rapid pathogen identification and antimicrobial susceptibility testing for hospital microbiology labs treating critically ill patients.
Ownership category
akta.pro rank

Pattern Bioscience industry classification

Industry
Product category
Clinical Microbiology Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAAAC
Microbiology & Infectious Disease Diagnostics (Culture/ID/AST)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Rapid antimicrobial susceptibility testing
  • Clinical microbiology diagnostics
  • Single-cell microbiology platform
  • Bacterial pathogen identification
  • Antimicrobial resistance diagnostics

Where Pattern Bioscience is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Pattern Bioscience business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Diagnostic Testing Platform and Assays: Pattern Bioscience generates revenue through the sale of its single-cell microbiology diagnostic system and associated ID/AST assay panels (Pneumonia ID/AST Panel, Bacteremia ID/AST Panel). The company is pre-commercial as of early 2026, preparing for first U.S. commercial launch following FDA 510(k) clearance of the Pneumonia ID/AST Panel.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Pattern Bioscience product offering

Product offering

Core offering

Pattern Bioscience develops and plans to commercialize a single-cell microbiology (Digital Culture™) diagnostic platform that isolates individual live bacterial cells in picovolume-scale droplets and uses machine learning to interpret their metabolic patterns. The platform is intended to deliver pathogen identification and phenotypic antimicrobial susceptibility testing (ID/AST) directly from clinical specimens in hours instead of the 2–4 days required by traditional culture-based methods. Initial commercial products target the Pneumonia ID/AST Panel for critically ill pneumonia patients and the Bacteremia ID/AST Panel for bloodstream infections, sold to hospital clinical microbiology laboratories.

Product overview

Pattern Bioscience offers a single-cell microbiology platform as its core technology, with two primary test panels: the Pneumonia ID/AST Panel for respiratory infections and the Bacteremia ID/AST Panel for bloodstream infections. The platform bypasses traditional culture steps by isolating and analyzing individual bacterial cells captured in droplets, delivering rapid pathogen identification and phenotypic antimicrobial susceptibility results in hours rather than days. The Pneumonia Panel analyzes bacterial cells directly from respiratory specimens, while the Bacteremia Panel works directly from positive blood culture samples.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pattern Pneumonia ID/AST Panel Rapid identification and phenotypic antimicrobial susceptibility testing (ID/AST) panel designed for critically ill patients hospitalized with severe pneumonia, delivering pathogen ID and susceptibility results in hours rather than the 2–4 days required by culture-based methods. Analyzes bacterial cells directly from respiratory specimens using single-cell microbiology, and received FDA Breakthrough Device Designation in December 2021.
  • Pattern Bacteremia ID/AST Panel Identification and phenotypic antibiotic susceptibility testing panel designed to identify pathogens and provide AST directly from positive blood culture samples, eliminating the need for additional culturing and isolation steps to obtain faster phenotypic susceptibility results for bloodstream infections.
  • Single-Cell Microbiology (Digital Culture™) Diagnostic Platform Culture-free, rapid phenotypic testing platform that delivers clinically actionable bacterial identification and antimicrobial susceptibility results in hours. Uses single-cell isolation in picovolume-scale droplets combined with proprietary data science and machine learning to generate millions of measurements per run capturing all resistance mechanisms (known, unknown, genetic, epigenetic, simple, or complex) for the company's ID/AST panels.

Quantifiable outcome

  • Up to 50% of antibiotics prescribed in hospitals are unnecessary or inappropriate (CDC)
  • +4 more outcomes

Companies that use Pattern Bioscience

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Pattern Bioscience technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Pattern Bioscience partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Pattern Bioscience competitors and assessment

Company assessment

Direct peers

  • Accelerate Diagnostics: Direct competitor developing rapid phenotypic ID/AST for bloodstream and other serious infections; acquired by bioMérieux in 2022. Competes head-to-head with Pattern on the same hospital bench for time-to-AST in critical care settings.
  • Specific Diagnostics: Developed a rapid AST instrument using metabolomic signaling — the closest analogue to Pattern's single-cell approach. Acquired by bioMérieux in 2022; Pattern's VP Sales led sales at Specific prior to the acquisition.
  • Qvella Corporation: Early-stage company developing rapid culture-free ID/AST directly from positive blood cultures, addressing the same unmet need as Pattern's Bacteremia ID/AST Panel and Bacteremia product roadmap.
  • Selux Diagnostics: Develops rapid phenotypic AST to deliver antibiotic susceptibility results in hours directly from clinical samples; competed against Pattern in the AMR Diagnostics Challenge and operates in the same FDA Breakthrough Designation / sepsis-decision-making category.
  • T2 Biosystems: Develops T2Bacteria and T2Candida panels for direct-from-blood rapid identification without culture; overlaps with Pattern's bloodstream infection roadmap and the clinical unmet need around sepsis diagnostics.

Broad incumbents

  • bioMérieux: Global leader in clinical microbiology (VITEK, BIOFIRE FilmArray, BACT/ALERT). Acquired both Accelerate Diagnostics and Specific Diagnostics. Sets the reimbursement and workflow precedent Pattern's commercial team must navigate.
  • Becton Dickinson (BD): Broad diagnostics incumbent offering the BD MAX molecular platform, BD Phoenix automated AST, and established MALDI workflow partnerships. Competes across ID/AST categories where Pattern plans to expand.
  • Bruker Corporation: Operates the MALDI Biotyper, the dominant rapid MALDI-TOF identification workflow in clinical microbiology labs; the incumbent alternative to single-cell phenotypic ID that Pattern's Pneumonia Panel must displace or complement.
  • Cepheid (Danaher): GeneXpert and Xpress systems are rapidly deployed across U.S. hospital microbiology labs for molecular diagnostics, including for bloodstream and respiratory panels, and represent the typical workflow that Pattern's phenotypic approach must clinically displace.
  • Roche Diagnostics: Acquired GenMark Diagnostics (eXpert rapid molecular) for ~$1.8B and operates cobas/coba platforms spanning microbiology and infectious disease; relevant as the strategic acquirer archetype for novel hospital diagnostics with KOL-led commercial traction.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pattern Bioscience social profiles

Digital presence

Pattern Bioscience compliance and trust

Trust signal

Compliance1 record

Pattern Bioscience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pattern Bioscience leadership team

Management profile

Number of profiles

Profiles19 records

Pattern Bioscience funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pattern Bioscience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pattern Bioscience

What does Pattern Bioscience do?

Pattern Bioscience develops and plans to commercialize a single-cell microbiology (Digital Culture™) diagnostic platform that isolates individual live bacterial cells in picovolume-scale droplets and uses machine learning to interpret their metabolic patterns. The platform is intended to deliver pathogen identification and phenotypic antimicrobial susceptibility testing (ID/AST) directly from clinical specimens in hours instead of the 2–4 days required by traditional culture-based methods. Initial commercial products target the Pneumonia ID/AST Panel for critically ill pneumonia patients and the Bacteremia ID/AST Panel for bloodstream infections, sold to hospital clinical microbiology laboratories.

Is Pattern Bioscience a public or private company?

Pattern Bioscience is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pattern Bioscience founded?

Pattern Bioscience was founded in 2016. It employs 51 to 100 people.

Where is Pattern Bioscience based?

Pattern Bioscience is headquartered in Austin, United States, in the North America region.

How does Pattern Bioscience make money?

One revenue line is on record: diagnostic Testing Platform and Assays.

Who are Pattern Bioscience's main competitors?

Direct peers on record are Accelerate Diagnostics, Specific Diagnostics, Qvella Corporation, Selux Diagnostics and T2 Biosystems. Broad incumbents are bioMérieux, Becton Dickinson (BD), Bruker Corporation, Cepheid (Danaher) and Roche Diagnostics.

Does Pattern Bioscience have an API?

No public API is recorded for Pattern Bioscience.

What industry is Pattern Bioscience in?

Pattern Bioscience's product category is Clinical Microbiology Diagnostics. Its primary akta.pro industry code is HLAHAAAC, Microbiology & Infectious Disease Diagnostics (Culture/ID/AST), with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacePattern Bioscience Surpasses 1,000 Samples in Multi-Center Clinical Trial of Rapid Pneumonia DiagnosticPattern Bioscience announced that more than 1,000 samples have been enrolled in its ongoing multi-center U.S. clinical trial evaluating the Pattern Pneumonia ID/AST Panel, marking the halfway point toward its target of approximately 2,000 samples across 11 external clinical sites. The pivotal trial is designed to support a 510(k) regulatory submission for what would be the first culture-free, rapid phenotypic susceptibility testing panel for critically ill pneumonia patients, delivering pathogen identification and antimicrobial susceptibility results in hours rather than the current two to four days. The company has aligned with the FDA on its validation strategy, expects to complete enrollment by mid-year and submit its data package in the third quarter, and holds FDA Breakthrough Device Designation along with a BARDA contract valued at up to $40.9 million.GlobeNewswireLateral Flow Assay Market Projected to Reach US$ 17.66 Billion by 2035, Reflecting Ongoing Innovation and IP Activity | Astute AnalyticaThe global lateral flow assay market was valued at USD 10.84 billion in 2025 and is projected to reach USD 17.66 billion by 2035, growing at a compound annual growth rate of 5.0% over the forecast period 2026–2035, driven by post-pandemic healthcare shifts, rising infectious disease burdens, and expanded government testing contracts. The market is segmented by product (LFA kits commanding 71.9% share), indication (infectious diseases at 72.2%), technique (sandwich assay at 48%), and end users (hospitals and clinics at 38.8%), with key players including QuidelOrtho, Abbott, and others investing in multiplex testing, nanoparticle sensitivity enhancements, and digital reader technologies. Regulatory approvals are accelerating, with the FDA issuing 1,507 510(k) clearances in the first half of 2024, while BARDA and NIH funding are de-risking R&D through contracts such as the USD 40.9 million award to Pattern Bioscience and the USD 45 million contract to Selux Diagnostics.LwLatham & Watkins Advises Pattern Bioscience in US$43 Million Series D FinancingPattern Bioscience has raised US$43 million in Series D financing led by AMR Action Fund, Illumina Ventures, and Omnimed Capital to advance its pneumonia diagnostic technologies. The funds will support a multi-center clinical trial and regulatory submission for the Pneumonia ID/AST Panel, which holds Breakthrough Device Designation from the FDA. Latham & Watkins LLP acted as legal counsel for Pattern Bioscience during this transaction.SecSEC FORM DPattern Bioscience, Inc. filed a Form D notice with the SEC disclosing an exempt offering of securities under Regulation D, indicating the company has raised approximately $44.2 million out of a disclosed total offering amount of $61.2 million, with the first sale occurring on July 31, 2025. The Austin, Texas-based biotechnology company, incorporated in Delaware, reported having 6 investors and disclosed the offering under Rule 506(b) and Rule 506(c) exemptions from securities registration requirements. The filing, signed by CEO Carey-Ann Burnham on August 18, 2025, indicates approximately $17 million remains to be sold under this offering.PR NewswireAdvances in Big Data for Precision Medicine, Novel Technologies to Determine a Pathogen's Susceptibility to Antibiotics, the Microbiome's Impact on Childhood Undernutrition, and More Draw Nearly 20,00The Association for Diagnostics and Laboratory Medicine (ADLM), formerly AACC, held its 75th anniversary annual scientific meeting and clinical lab expo in Anaheim, California from July 23-27, 2023, attracting nearly 20,000 laboratory medicine professionals and 910 exhibitors. The event featured sessions on big data for precision medicine, microbiome-directed therapies for childhood undernutrition, and healthcare equity, with Pattern Bioscience winning the Disruptive Technology Award for its single-cell microbiology technology that can identify pathogens and determine antibiotic susceptibility. The organization officially rebranded from AACC to ADLM during the meeting and announced its 2024 gathering will take place in Chicago.American City Business JournalsPattern Bioscience raises nearly $29M; Austin bacteria-fighting startup seeks FDA reviewAustin-based Pattern Bioscience announced the closing of a $28.7 million Series C funding round to support the development of its rapid phenotypic test platform and FDA regulatory submissions for pneumonia diagnostics. The investment was led by Illumina Ventures and Omnimed Capital, adding to the company's total capital raised of $68 million since its founding in 2016. This financing enables Pattern to expand its clinical studies and workforce as it seeks to address antibiotic resistance through faster pathogen identification.Venture Capital Access OnlinePattern Bioscience Secures $28.7 Million in Series C FinancingPattern Bioscience announced the completion of a $28.7 million Series C financing round led by Illumina Ventures and Omnimed Capital, bringing its total funding to $68 million. The company intends to use these funds to finalize the development of its single-cell microbiology diagnostic platform and submit its initial pneumonia test for FDA regulatory review.PatternPattern Bioscience Secures $28.7 Million in Series C FinancingPattern Bioscience announced the completion of a $28.7 million Series C financing round led by Illumina Ventures and Omnimed Capital, bringing its total funding to $68 million. The company intends to use these funds to finalize the development of its single-cell microbiology diagnostic platform for infectious diseases and submit its initial pneumonia test for FDA regulatory review.BioSpacePattern Bioscience Secures $28.7 Million in Series C FinancingPattern Bioscience completed a $28.7 million Series C financing round led by Illumina Ventures and Omnimed Capital, bringing its total funding to $68 million. The company intends to use these funds to finalize the development of its single-cell microbiology diagnostic platform and submit its initial pneumonia test for FDA regulatory review.VC News DailyPattern Bioscience Scoops Up $28.7M Series CPattern Bioscience, an Austin-based diagnostics company specializing in rapid bacterial infection testing, completed a $28.7 million Series C financing round. The funding was co-led by Illumina Ventures and Omnimed Capital with participation from the Antimicrobial Resistance Action Fund and Daleshaw Ltd, bringing the company's total funding to $68 million. The company's single-cell microbiology technology provides culture-free, rapid phenotypic testing that delivers results in hours versus days required by traditional culture methods, targeting critically ill patients with pneumonia and bacteremia.